PDCD1 and triple-negative breast carcinoma: In models of colorectal and triple-negative breast cancer, Dasatinib selectively inhibits CAFs and remodels the extracellular matrix, thereby promoting the deep infiltration of drugs and CD8+ T cells into the tumor, converting immunologically “cold” tumors into “hot” tumors and significantly enhancing the efficacy of anti-PD-1 immunotherapy [44,45].